Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian cancer called high-grade serous, primary peritoneal, or fallopian tube cancer.
- Your cancer is resistant to platinum-based chemotherapy, meaning it came back within 6 months of treatment.
- You have had 1 to 3 prior treatments for your cancer and your doctor thinks single-drug therapy is appropriate next.
- You have a tumor tissue sample that can be tested for FRα levels.
- You have not had prior treatment with drugs targeting FRα or a type of chemotherapy called TOP1i ADC.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial tests a new drug called BL-M07D1 against standard chemotherapy for people with HER2-positive ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. It aims to find out if BL-M07D1 works better than the doctor's choice of chemo.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.